Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Refusal-To-File Slows Acorda’s Promising Niche MS Drug

This article was originally published in The Pink Sheet Daily

Executive Summary

Firm may need to refile NDA for mobility-boosting Fampridine-SR.

You may also be interested in...



Chelsea Vows To Resolve Latest Regulatory Woes With Northera Quickly

Technical deficiencies foil the resubmission of Chelsea Therapeutics’ Northera. The company thinks it can resolve the problems quickly and some analysts expect a relatively short delay of one or two months to the user fee date.

Acorda's MS Drug Amaya Panel Review Leaves Little Time To React

The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.

Acorda's MS Drug Amaya Panel Review Leaves Little Time To React

The Peripheral and Central Nervous System Drugs Advisory Committee will review the mobility-enhancing drug one week before its scheduled PDUFA date.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel